ArticleFrontiers in neurology2021
Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- The Role of MicroRNAs in Progressive Supranuclear Palsy-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Article
- Epidemiology of Progressive Supranuclear Palsy in Navarre, Spain: A Population-Based Study.European journal of neurology · 2026Observational
- Progressive Supranuclear palsy (PSP) disease progression, management, and healthcare resource utilization: a retrospective observational study in the US and Canada.Orphanet journal of rare diseases · 2024Observational
- Dysphagia in progressive supranuclear palsy: A scoping review.Clinical parkinsonism & related disorders · 2024Article
- Investigating differences in young- and late-onset progressive supranuclear palsy.Journal of neurology · 2023Article
- Progressive supranuclear palsy's economical burden: the use and costs of healthcare resources in a large health provider in Israel.Journal of neurology · 2023Article
- Can accelerated ageing models inform us on age-related tauopathies?Aging cell · 2023Review
- Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy.Journal of neuropathology and experimental neurology · 2023Article
- Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy.Acta neuropathologica · 2022Article
- Disease modification in Parkinsonism: obstacles and ways forward.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel.Brain sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.